Regulus Therapeutics Inc (NASDAQ:RGLS) – Research analysts at Wedbush issued their FY2022 EPS estimates for shares of Regulus Therapeutics in a note issued to investors on Thursday. Wedbush analyst L. Moussatos anticipates that the biopharmaceutical company will earn $0.47 per share for the year. Wedbush has a “Outperform” rating and a $4.00 price objective on the stock.
A number of other research analysts have also recently issued reports on RGLS. Zacks Investment Research cut shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 18th. Chardan Capital reissued a “neutral” rating on shares of Regulus Therapeutics in a research note on Tuesday, January 16th. Leerink Swann began coverage on shares of Regulus Therapeutics in a research note on Friday, January 5th. They issued an “outperform” rating and a $2.00 price objective on the stock. Finally, Needham & Company LLC reissued a “hold” rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company’s stock. Regulus Therapeutics has a consensus rating of “Hold” and an average price target of $2.50.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. BVF Inc. IL grew its stake in shares of Regulus Therapeutics by 7.9% during the fourth quarter. BVF Inc. IL now owns 13,974,249 shares of the biopharmaceutical company’s stock worth $14,533,000 after buying an additional 1,025,020 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Regulus Therapeutics by 215.7% during the fourth quarter. Renaissance Technologies LLC now owns 137,589 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 94,000 shares during the period. Ascend Capital LLC acquired a new position in shares of Regulus Therapeutics during the fourth quarter worth $1,053,000. Victory Capital Management Inc. lifted its holdings in shares of Regulus Therapeutics by 18.2% during the fourth quarter. Victory Capital Management Inc. now owns 327,770 shares of the biopharmaceutical company’s stock worth $341,000 after purchasing an additional 50,530 shares during the period. Finally, GSA Capital Partners LLP lifted its holdings in Regulus Therapeutics by 44.8% in the third quarter. GSA Capital Partners LLP now owns 203,815 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 63,100 shares during the period. 59.32% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://sportsperspectives.com/2018/02/14/equities-analysts-offer-predictions-for-regulus-therapeutics-incs-fy2022-earnings-rgls.html.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.